Publikationen, an denen er mitarbeitet Vanessa Roldan Schilling (97)

2023

  1. Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases

    International Journal of Molecular Sciences, Vol. 24, Núm. 22

  2. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

    Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323

2021

  1. Anticoagulant therapy in patients with congenital FXI deficiency

    Blood Advances, Vol. 5, Núm. 20, pp. 4083-4086

  2. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma

    Journal of Thrombosis and Thrombolysis, Vol. 52, Núm. 3, pp. 848-853

2020

  1. ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant

    Molecular Genetics and Genomic Medicine, Vol. 8, Núm. 8

  2. Factor XII in PMM2-CDG patients: Role of N-glycosylation in the secretion and function of the first element of the contact pathway

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

  3. Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation

    Mayo Clinic Proceedings, Vol. 95, Núm. 11, pp. 2360-2369

  4. Pilot study on the role of circulating mirnas for the improvement of the predictive ability of the 2mace score in patients with atrial fibrillation

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-11

  5. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: The Murcia AF project

    Thrombosis and Haemostasis, Vol. 120, Núm. 8, pp. 1200-1207

2019

  1. Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under Vitamin K antagonists

    QJM, Vol. 112, Núm. 3, pp. 183-188

  2. Increasing therapy-related myeloid neoplasms in multiple myeloma

    European Journal of Clinical Investigation, Vol. 49, Núm. 2

  3. Murcia atrial fibrillation project II: Protocol for a prospective observational study in patients with atrial fibrillation

    BMJ Open, Vol. 9, Núm. 12

  4. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores

    Stroke, Vol. 50, Núm. 6, pp. 1372-1379

2018

  1. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA 2 DS 2 -VASc and HAS-BLED scores using multiple biomarkers

    Annals of Medicine, Vol. 50, Núm. 1, pp. 26-34

  2. A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials

    Mayo Clinic Proceedings, Vol. 93, Núm. 8, pp. 1065-1073

  3. Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality

    International Journal of Clinical Practice, Vol. 72, Núm. 3

  4. Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency

    Thrombosis Research, Vol. 163, pp. 64-70

  5. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in ‘real-world’ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients

    International Journal of Cardiology, Vol. 254, pp. 125-131

  6. MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients with Atrial Fibrillation

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 38, Núm. 4, pp. 892-902

  7. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation

    European Journal of Clinical Investigation, Vol. 48, Núm. 6